Company overview
Aria Pharmaceuticals is a preclinical-stage company developing novel small molecule therapies for complex diseases including lupus, idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD), and non-alcoholic steatohepatitis (NASH). It employs a proprietary AI platform that integrates 25 data sources and over 65 methods to identify high-efficacy candidates, achieving a 30-fold higher success rate in animal efficacy studies compared to traditional approaches. The company has filed provisional patents for lead candidates like TXR-711 (lupus), TXR-1002 (IPF), and TXR-1210 (CKD), with plans to advance into IND-enabling studies.
Industry categories: CRO & Clinical Services. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://ariapharma.com
- Categories
- CRO & Clinical Services
- Markets served
- United States & Americas
- Keywords
- aria pharmaceuticals, ai drug discovery, small molecule therapeutics, lupus treatment, ipf therapy, preclinical pharma
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What therapeutic areas does Aria Pharmaceuticals target?
- Aria focuses on complex, hard-to-treat diseases including lupus, idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD), and non-alcoholic steatohepatitis (NASH), with 12-18 programs in preclinical development.
- What is Aria's AI platform capable of?
- The proprietary AI engine combines data from 25 sources, gene expression, clinical data, and a 2 million molecule library to model diseases in silico, predict efficacy, and identify novel mechanisms, delivering a 30-fold improvement in hit rates for preclinical efficacy.
- What is the development stage of Aria's pipeline?
- Aria is preclinical-stage with positive efficacy and safety data across multiple candidates; it has filed six provisional US patents and plans IND-enabling studies, supported by a lean $15M budget.
Related editorial coverage
- Verge Rebrands AI Drug Discovery After Trial Setback
- AstraZeneca's SAPHNELO Autoinjector Approved by FDA for Self-Administration in Lupus Treatment
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
Explore lab tools and QA/QC resources for R&D teams.
